

How to Read the FoundationOne™ Report

THE FIRST PAGE OF THE REPORT SHOWS
the patient and ordering physicians information...

The genomic alterations identified in the hundreds of genes assayed...

The targeted therapies that may be relevant based on those genomic alterations both in the patients tumor type and in other tumor types...

and whether there are relevant clinical trials.



Genomic Alterations Detected	FDA Approved Therapies (in patient's tumor type)	FDA Approved Therapies (in another tumor type)	Potential Clinical Trials
EGFR N771_P772>KFP	Erlotinib Gefitinib	Cetuximab Panitumumab	Yes, see clinical trials section
CCND1 amplification	None	None	Yes, see clinical trials section
ARID1A Q633*	None	None	None



The second page of the report contains a more detailed interpretive statement that references the frequency of the genomic alteration, its biological implication and what it may mean for the patient.



The Therapies section of the report provides more details on approved therapies to which the patient's cancer may be sensitive or resistant based on its genomic profile.



The clinical trials section of the report provides some detail on currently available clinical trials for which the patient may be eligible based on genomic profile of the patient's cancer. This section also provides guidance to the physician to help identify other trials in publicly available databases for which the patient may be eligible.



The appendix of the report contains the full list of genes assayed in the test so you can see all the genes in which there were no alterations found. The appendix also lists the references used in creating the report and technical notes about the test.